
4 New Drugs Approved for Primary Care: Q3 2022
Novel NMDA receptor antagonist approved for the treatment of major depressive disorder, first topical PDE4i approved for plaque psoriasis, and more.
The third quarter has come and gone, which means Patient Care Online has compiled another list of drugs approved by the US Food and Drug Administration for conditions that are often seen in primary care. In the slides below, find details on a novel rapid-acting treatment for major depressive disorder that was the first of its kind to receive approval from FDA, a novel treatment for plaque psoraisis, and more.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.










































































































































































































































































































